|Bid||0.0000 x 3100|
|Ask||0.0000 x 1100|
|Day's Range||3.9500 - 4.1100|
|52 Week Range||1.8200 - 4.7900|
|Beta (5Y Monthly)||2.05|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]
Every investor in Agenus Inc. (NASDAQ:AGEN) should be aware of the most powerful shareholder groups. Institutions will...
Agenus Inc. (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
As of late, it has definitely been a great time to be an investor in Agenus.
On CNBC's "Mad Money Lightning Round," Jim Cramer said that Taiwan Semiconductor Mfg. Co. Ltd. (NYSE: TSM) is a great stock.Inseego Corp (NASDAQ: INSG) is a 5G company that Cramer likes and he is sticking by it.Agenus Inc (NASDAQ: AGEN) is a momentum play and it is not doing anything, said Cramer. He would like to hear some big news from the company.Instead of Eldorado Resorts Inc (NASDAQ: ERI), Cramer would buy Penn National Gaming, Inc (NASDAQ: PENN).Cramer is a buyer of AstraZeneca plc (NYSE: AZN). He thinks it is a well-run company with some great franchises.Halliburton Company (NYSE: HAL) should be sold, believes Cramer.Alaska Air Group, Inc. (NYSE: ALK) is a very well-run airline, but Cramer would rather buy Southwest Airlines Co (NYSE: LUV) because it is the best run airline.See more from Benzinga * Cramer Shares His Thoughts On Marriott, Tegna And More * Cramer Shares His Thoughts On VectoIQ, Yext And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
In this daily bar chart of AGEN, below, we can see three rapid and sharp moves. The daily On-Balance-Volume (OBV) line shows improvement from lows in March and May but trading volume seems to come in spurts. In this weekly bar chart of AGEN, below, we can see a large sideways trading range market.
Agenus (AGEN) signs an exclusive collaboration and license agreement with Chinese company, Betta Pharmaceuticals, for the development and commercialization of balstilimab and zalifrelimab.
What happened Agenus (NASDAQ: AGEN), a small-cap immunotherapy company, saw its stock gain a healthy 51% during the month of May, according to data from S&P Global Market Intelligence. The biotech's shares perked up late last month in response to a positive clinical update for its cancer immunotherapy pipeline presented at the American Society for Clinical Oncology (ASCO) annual meeting.
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) * Agenus Inc (NASDAQ: AGEN)(announced FDA clearance of its IND for evaluating its allogeneic iNKT therapy as a COVID-19 treatment option) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)(moved on a positive readout for a rival ulcerative colitis drug from Bristol-Myers Squibb Co (NYSE: BMY)) * argenx SE - ADR (NASDAQ: ARGX) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * Cardiff Oncology Inc (NASDAQ: CRDF) * Fortress Biotech (NASDAQ: FBIO) * Imara Inc (NASDAQ: IMRA) * Kala Pharmaceuticals Inc (NASDAQ: KALA) * ORIC Pharmaceuticals Inc (NASDAQ: ORIC) * Protara Therapeutics Inc (NASDAQ: TARA) * Qiagen NV (NYSE: QGEN) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) * Tenax Therapeutics Inc (NASDAQ: TENX)( announced a positive Phase 3 readout) * Trillium Therapeutics Inc (NASDAQ: TRIL) * Turning Point Therapeutics Inc (NASDAQ: TPTX) * Unity Biotechnology Inc (NASDAQ: UBX) * Vermillion, Inc. (NASDAQ: VRML) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB)(announced FDA acceptance of its BLA for Danyelza for the treatment of patients with relapsed/refractory high-risk neuroblastoma)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 2) * Exagen Inc (NASDAQ: XGN)Stocks In Focus Novartis Announces 3-Month Extension In Regulatory Review Period For Multiple Sclerosis Drug Novartis AG (NYSE: NVS) announced the receipt of a notification from the FDA, extending the review of its sNDA for ofatumumab for patients with relapsing multiple sclerosis. The company said the regulatory action would happen in September.The company said it will continue to work with the FDA to complete the review as soon as possible. It also said additional regulatory filings are underway and that European approval of ofatumumab is expected in the second quarter of 2021.FSD Pharma Gets FDA Nod For Initiating Proof-of-concept Study Of COVID-19 Treatment Candidate FSD Pharma Inc (NASDAQ: HUGE) said the FDA has given it permission to submit an IND for the use of its FSD-201 to treat COVID-19, the disease caused by the SARS-CoV-2 virus. The company said it's focused on developing FSD-201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.In pre-market trading, the stock was galloping 129.03% to $7.10.Novavax Partners With AGC Biologics to Manufacture Adjuvant Component of Coronavirus Vaccine partner AGC Biologics said Novavax, Inc. (NASDAQ: NVAX) has selected it for manufacturing Matrix-M, the adjuvant component of the latter's SARS-CoV-2 vaccine candidate, NVX-CoV2373, which enhances the immune response and stimulate high levels of neutralizing antibodies. AGC said it will optimize process development for scaled-up production of Matrix-M to significantly increase Novavax' capacity to deliver doses in 2020 and 2021.Related Link: Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates Anika's CFO to Quit Following a Transition Period Anika Therapeutics Inc (NASDAQ: ANIK) said its CFO Sylvia Cheung communicated her decision to relinquish office, effective August 21, 2020. The company said it has initiated a search to identify a successor.AnPac Bio Names New CFO AnPac Bio-Medical Science Co Ltd - ADR (NASDAQ: ANPC) announced the appointment of Jinqiu Tang as CFO of the company, effective June 1, succeeding Yu Zhang, who stepped down, effective May 31.Offerings Evofem Biosciences, Inc. (NASDAQ: EVFM) said it has priced its underwritten public offering of 28.50 million shares at $3.50 per share, for raising gross proceeds of $100 million. All the shares are being offered by the company. The company expects the offering to close on or about June 5.In pre-market trading, Evofem shares were slipping 12.66% to $4.07.EULAR 2020 Congress Presentations Eli Lilly And Co (NYSE: LLY) announced long-term data on Olumiant in patients with moderate to severe rheumatoid arthritis is to be presented at the at the European League Against Rheumatism, or EULAR, 2020 E-Congress. The study, according to the company, found that among patients with an inadequate response to methotrexate, or MTX, from drug initiation up to three years, 52% of patients initially treated with Olumiant (+MTX) were in a state of low disease activity at week 24 and this rate was maintained through week 148. The company also shared updated integrated safety analysis of Olumiant in the treatment of RA in patients treated up to 8.4 years, which showed no new safety signals.Replimune Group Inc (NASDAQ: REPL) announced new interim data from the study of patients with melanoma and non-melanoma skin cancers treated with RP1 combined with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo, which showed the investigational asset continued to provide strong support for its lead indications of cutaneous squamous cell carcinoma (CSCC) and anti-PD-1 refractory melanoma.On The Radar Clinical Readouts Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) will present at the EULAR, 2020 E-Congress Phase 1 data for mavrilimumab in COVID-19 treatment.IPOs San Francisco, California-based Pliant Therapeutics, Inc. priced its upsized initial public offering of 9-million share offering at $16, the upper bound of the estimated range of $14-$16. The clinical stage biopharma focused on discovering and developing novel therapies for the treatment of fibrosis said its shares will be listed on the Nasdaq under the ticker symbol PLRX.See more from Benzinga * The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To 0M In Biotechs * The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shares of Agenus (NASDAQ: AGEN) jumped over 23% today after the company announced a presentation at the American Society of Clinical Oncology (ASCO) meeting discussing the progress of AGEN1181 in solid-tumor cancers. The drug candidate delivered clinical benefit in 70% of patients with advanced tumors in the small-scale study, both as a monotherapy and in combination with another drug candidate from the company. If the results can hold up in larger clinical trials, AGEN1181 might have broad potential to improve outcomes for patients with a wide array of solid tumor cancers.
Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.
Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.
Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.
The FDA clears Agenus' (AGEN) IND application for allogeneic iNKT therapy, agenT-797, which is being developed to treat cancer as well as the deadly COVID-19 pandemic.
Thank you for standing-by and welcome to Agenus' First Quarter 2020 Conference Call. Dr. Buell, please go ahead. Before we start, we'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development and regulatory plans and timelines as well as timelines for data release and cash projections.